Actualités

GeneDx Holdings delivers AI-powered clinical and genomic data analysis for healthcare providers seeking precision medicine solutions.

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ISRG's SP platform sees Q1 2026 procedures jump 68%, with new approvals and tools raising a key question: TAM expansion or procedure shift?

Globus Medical, Inc. (NYSE:GMED) was among the stocks Jim Cramer looked at as he explained the need for a tame bond market for the stock market to go higher. A caller asked for Cramer’s thoughts on the company, and he remarked: Okay, this group in particular, the medical device group, is hated in this market. […]

Boston Scientific (NYSE:BSX) reported positive pivotal trial results for its SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter. The FRACTURE trial met all primary safety and effectiveness endpoints in patients with severely calcified coronary artery disease. The company plans to use these data to support a regulatory submission for SEISMIQ 4CE. Boston Scientific is a major player in interventional cardiology, with products focused on treating complex coronary and structural heart...

TCW Funds, an investment management firm, published its first-quarter 2026 investor letter for the ‘TCW Concentrated Large Cap Growth Fund.’ A copy of the letter is available to download here. The first quarter was marked by volatility in equity markets, driven by geopolitical tensions, concerns about the private credit sector, a government shutdown, and ongoing […]

ABT's EPD unit posts 9% Q1 sales growth as biosimilars and emerging market demand support its long-term expansion plans.

With a 5-year average revenue growth rate of 13.52%, Boston Scientific Corporation (NASDAQ:BSX) is included among the 11 Best Long Term US Stocks to Buy Right Now. On May 19, Baird lowered its price recommendation on Boston Scientific Corporation (NASDAQ:BSX) to $75 from $78. It reiterated an Outperform rating on the shares. The firm updated its model […]

Healthcare stocks rose late Tuesday afternoon, with the NYSE Healthcare Index and the State Street H

Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index adding 1.1% and the State S

Boston Scientific (BSX) stock declined 47% over the last 12 months to trade near $57. Despite total revenues growing 17.4% to $20.6 billion and net income margins improving to 17.3%, the P/E multiple contracted by 70%. The selloff was triggered by a Q4 2025 GAAP EPS miss and a significant full-year 2026 organic growth guidance cut. The company's management lowered the target from a 10 to 11% range down to 6.5 to 8.0%, attributing the reset to greater-than-expected market share loss in the Electr

Boston Scientific plans to use the IDE trials results to support a regulatory filing of its Seismiq 4CE Coronary catheter with the FDA.

According to the average brokerage recommendation (ABR), one should invest in Boston Scientific (BSX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Companies In The Article Are:REGN,D,NEE,STX and BSX

With the study results, Boston Scientific plans a regulatory submission for the intravascular lithotripsy treatment for patients with severely calcified coronary artery disease.

Boston Scientific may acquire full ownership of MiRus’ TAVR business for an additional $3bn after achieving certain milestones.

Boston Scientific (NYSE:BSX) announced a US$2b accelerated share repurchase program. The company also agreed to invest US$1.5b in MiRus, securing a significant equity stake. The MiRus deal includes an exclusive option related to the company’s transcatheter aortic valve replacement (TAVR) business. Boston Scientific, a large medical device company focused on cardiovascular and other interventional therapies, is pairing a sizeable capital return with a move deeper into structural heart...

The S&P 500 Index ($SPX ) (SPY ) on Monday closed down -0.07%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.32%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.45%. June E-mini S&P futures (ESM26 ) fell -0.12%, and June E-mini Nasdaq futures...

Healthcare stocks rose late Monday afternoon, with the NYSE Healthcare Index and the State Street He

The deal gives Boston Scientific a 34% stake in MiRus and an option to buy its TAVR business for an additional $3 billion

BSX expands into fast-growing medtech segments with acquisitions spanning urology, pain management and vascular devices.

(Bloomberg) -- For years, there was only one way for mom-and-pop investors to buy into Elon Musk’s vision: shares of Tesla Inc. That’s about to change — and it’s a serious risk for Tesla investors. Most Read from BloombergStocks Fall, Oil Rises as Hormuz Deal Hopes Fade: Markets WrapBillionaire Rinehart Bets $100 Million on US Defense StocksIranian Media Said US Offered Interim Waiver on Oil SanctionsUS and Iran Far From Deal as Bond Rout Piles Pressure on TrumpWinners and Losers From Trump and

Stock Gains Following Capital Allocation AnnouncementsShares of Boston Scientific (NYSE:BSX) rose 2. 1% in premarket trading on Monday after the company announced a $2 billion accelerated share repurchase program alongside a $1.

Healthcare stocks were declining pre-bell Monday, with the State Street Health Care Select Sector SP

The deal gives Boston Scientific a 34% equity stake in MiRus and an option to acquire its TAVR platform by making additional payments totaling $3 billion.

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.

Moby summary of Elutia Inc.'s Q1 2026 earnings call

BSX expands global reach with strong APAC growth, FARAPULSE momentum and new approvals driving gains across Europe and China.

Boston Scientific Corporation (NYSE:BSX) was one of the stocks on which Jim Cramer shared his take, explaining that dot-com analogies do not hold up in this market. During the lightning round, a caller asked if they should sell or buy more BSX shares. Cramer replied: I hate to sell these. I don’t mean to sound […]

Danaher Corporation (NYSE:DHR) was one of the stocks on which Jim Cramer shared his take, explaining that dot-com analogies do not hold up in this market. Cramer called it a “one-time excellent company,” as he said: For instance, Danaher, another one-time excellent company, has seen the stock just get pulverized after not-so-great quarters, or I […]